BioSpace News Archive

Bruker Corporation (Nasdaq: BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG , a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions.

Soligenix, Inc. today that the Company will deliver a corporate presentation at The Microcap Conference.

InflaRx Pharmaceuticals Inc. announced today that the Company has launched The InflaRx Commitment Program (Commitment Program).

FibroBiologics, Inc., a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has been notified by NASDAQ that trading of its common stock will commence on Wednesday, January 31, 2024.

Accuray Incorporated announced that the Providence Swedish Radiosurgery Center in Seattle, Washington is enhancing its cancer treatment capabilities with the purchase of the latest generation CyberKnife® S7™ System, the hospital’s second CyberKnife radiation delivery device purchase.

Wiley (NYSE: WLY and WLYB), one of the world’s largest publishers and a global leader in research and learning, will host its Investor Update today at 10 am E.T. to discuss the company’s business and financial outlook.

JCR Pharmaceuticals Co., Ltd. announced today that it will present six presentations at the 20th Annual WORLD Symposium ™ 2024, to be held February 4-9, 2024 in San Diego, Calif.

Domain to receive a grant over a five year period to support DT-7012 which is expected to start a Phase I study by mid-2025.

Prime Medicine, Inc. (Nasdaq: PRME) today announced that the Cystic Fibrosis Foundation (CF Foundation) has agreed to provide the Company with up to $15 million to support the development of Prime Editors for the treatment of Cystic Fibrosis (CF).

Ocular Therapeutix, Inc. (NASDAQ:OCUL) today announced that the U.S. Food and Drug Administration (FDA) has agreed to a Special Protocol Assessment (SPA) Agreement Modification for the Company’s pivotal Phase 3 SOL clinical trial of AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD).